2762.3000 21.20 (0.77%)
NSE Sep 22, 2025 15:31 PM
Volume: 81,247
 

2762.30
0.77%
Motilal Oswal
GSK Pharma (GLXO) delivered in-line 3QFY22 earnings after including profits from discontinued operations. While the pharma portfolio tracked doubledigit growth, it was offset to some extent by the lower off-take of vaccines because of the third COVID wave. With COVID receding, we expect a gradual revival in the vaccine business. We have tweaked our EPS estimates for FY22/FY23/24 by 2% to factor in :a) an improved outlook for the vaccine business, b) a better traction in brands...
GlaxoSmithKline Pharmaceuticals Ltd. is trading above its 200 day SMA of 2729.1
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended